Health Trials

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

ConditionsPulmonary Hypertension Due to Lung Diseases and HypoxiaPulmonary HypertensionInterstitial Lung Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUnited Therapeutics

About this trial

This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).

Eligibility criteria

Qualifiers

Adults aged 18 years or older

Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis

Autoimmune ILD

Chronic hypersensitivity pneumonitis

Disqualifiers

Confirmed diagnosis of Group 1, 2, 4, or 5 PH

Confirmed diagnosis of Group 3 PH associated with lung diseases and or hypoxia other than fibrotic ILD, as outlined in Inclusion Criterion 2.

Patients receiving inhaled treprostinil (Yutrepia™) at Baseline. Patients receiving other forms of PH therapy will be eligible for enrollment.

Trial design

Treatments tested in this trial

  • Prospective study assessments

Treatment groups

900 Participants
are divided into 4 treatment groups

Sponsors and collaborators

United Therapeutics

Lead sponsor

Source ClinicalTrials.gov